Unknown

Dataset Information

0

Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center.


ABSTRACT: Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trials. We performed a retrospective review of all patients with MBC who were enrolled in phase I clinical trials at the University of Colorado Cancer Center from January 2012 to June 2018. A total of 208 patients were identified. Patients had a mean age of 57 years and received on average 2.1 (range 0-10) prior lines of chemotherapy. The majority of patients had hormone receptor-positive/HER2-negative breast cancer (58.6%) and 30.3% had triple-negative breast cancer. The median progression free survival (PFS) was 2.8 months (95% CI, 2.3-3.9) and median overall survival (OS) was 11.5 months (95% CI, 9.6-13.2). Independent factors associated with longer PFS in multivariable analysis were treatment in a breast cancer-selective trial or cohort (p = 0.016), age >50 years (p = 0.002), and ≤2 prior lines of chemotherapy in the metastatic setting (p = 0.025). Phase I clinical trials remain a valuable option for select patients with MBC and enrollment should be encouraged when available.

SUBMITTER: Weiss JA 

PROVIDER: S-EPMC7724484 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center.

Weiss Jennifer A JA   Nicklawsky Andrew A   Kagihara Jodi A JA   Gao Dexiang D   Fisher Christine C   Elias Anthony A   Borges Virginia F VF   Kabos Peter P   Davis Sarah L SL   Leong Stephen S   Eckhardt Sue Gail SG   Diamond Jennifer R JR  

Cancer medicine 20201016 23


Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trials. We performed a retrospective review of all patients with MBC who were enrolled in phase I clinical trials at the University of Colorado Cancer Center from January 2012 to June 2018. A total of 208 patients were identified. Patients had a mean age  ...[more]

Similar Datasets

| S-EPMC8010246 | biostudies-literature
| S-EPMC4258414 | biostudies-literature
| S-EPMC6684862 | biostudies-literature
| S-EPMC6904523 | biostudies-literature
| S-EPMC5675623 | biostudies-literature
| S-EPMC6192009 | biostudies-literature
| S-EPMC5940334 | biostudies-literature
| S-EPMC4454458 | biostudies-literature
| S-EPMC2775645 | biostudies-literature